abstract：:Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...

journal_title：Cancer treatment reviews

authors： Cusack JC

更新日期：2003-05-01 00:00:00

abstract：:Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...

journal_title：Cancer treatment reviews

authors： Sakorafas GH

更新日期：2003-04-01 00:00:00

abstract：:The interactions of cisplatin with other anti-cancer agents on the DNA level have been studied extensively in pre-clinical experiments. In general, combination of cisplatin with an antimetabolite, taxane, or topoisomerase inhibitor, can result in a modulation of platinum pharmacology on the DNA, for example, enhanced ...

journal_title：Cancer treatment reviews

authors： Crul M,van Waardenburg RC,Beijnen JH,Schellens JH

更新日期：2002-12-01 00:00:00

abstract：:The role of adjuvant chemotherapy in patients with stage III colon cancer is now well established and 5-FU/LV should be the reference regimen to which new drugs are tested against in the adjuvant setting. In stage II colon cancer, because the risk of recurrence is lower, any absolute benefit of chemotherapy is likely ...

journal_title：Cancer treatment reviews

authors： Chau I,Cunningham D

更新日期：2002-10-01 00:00:00

abstract：:With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the ...

journal_title：Cancer treatment reviews

authors： Nuver J,Smit AJ,Postma A,Sleijfer DT,Gietema JA

更新日期：2002-08-01 00:00:00

abstract：:Epithelial ovarian cancer (EOC) is the most common gynaecological malignancy in the Western world and a leading cause of death. Patients with relapsed EOC are incurable and therefore the toxicity of palliative chemotherapy and effects on health-related Quality of Life are important factors. Several newer cytotoxic age...

journal_title：Cancer treatment reviews

authors： Stebbing J,Gaya A

更新日期：2002-04-01 00:00:00

abstract：:The technique of sentinel node biopsy (SNB) presents a great opportunity to reduce the morbidity of surgical treatment of breast cancer. Using either dye, isotope or a combination, after completing a learning process a sensitivity of 80-99% may be achieved. Most surgeons would aim for a sensitivity of 95% but this wil...

journal_title：Cancer treatment reviews

authors： Fentiman IS,Mansel RE

更新日期：2002-02-01 00:00:00

abstract：:The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells. The most commonly reported result in multi-modalit...

journal_title：Cancer treatment reviews

authors： Gomez GG,Hutchison RB,Kruse CA

更新日期：2001-12-01 00:00:00

abstract：BACKGROUND:Epidemiological evidence supports the existence of a survival advantage for female patients with melanoma. This survival advantage often persists when other prognostic variables are taken into account. The basis for this female advantage or male disadvantage is not established although female sex steroids ca...

journal_title：Cancer treatment reviews

authors： Molife R,Lorigan P,MacNeil S

更新日期：2001-08-01 00:00:00

abstract：:Prostate cancer is the most common malignancy in elderly men and is often associated with bone metastases. Although bone metastases are osteosclerotic, histological and biochemical studies clearly indicate an increase of both bone formation and bone resorption, providing the rational for using bisphosphonate as a pall...

journal_title：Cancer treatment reviews

authors： Garnero P

更新日期：2001-06-01 00:00:00

abstract：:Surgery has been considered the standard of care in patients with early-stage non-small cell lung cancer (NSCLC), as well as in some cases of stage III, for a long time. Poor survival after complete resection has led to the search for new therapeutic strategies such as combining anticancer treatments. However, at the ...

journal_title：Cancer treatment reviews

authors： Depierre A,Westeel V,Jacoulet P

更新日期：2001-04-01 00:00:00

abstract：:Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Environmental and Helicobacter pylori (Hp) acting early in life in a multistep and multifactorial process may cause intestinal type carcinomas, whereas genetic abnormalities are related more...

journal_title：Cancer treatment reviews

authors： Roukos DH

更新日期：2000-08-01 00:00:00

abstract：:There has been much progress in the understanding of the relationship between the immune system and colorectal cancer. This has led to the use of immunomodulatory therapy in the adjuvant and palliative treatment of the condition. Although attempts at the use of non-specific immunomodulation with agents such as levamis...

journal_title：Cancer treatment reviews

authors： Yip D,Strickland AH,Karapetis CS,Hawkins CA,Harper PG

更新日期：2000-06-01 00:00:00

abstract：:From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...

journal_title：Cancer treatment reviews

authors： Hofstra LS,de Vries EG,Mulder NH,Willemse PH

更新日期：2000-04-01 00:00:00

abstract：:Pancreatic cancer represents the fourth leading cause of cancer death in men and the fifth in women. Prognosis remains dismal, mainly because the diagnosis is made late in the clinical course of the disease. The need to improve the diagnosis, detection, and treatment of pancreatic cancer is great. It is in this type o...

journal_title：Cancer treatment reviews

authors： Sakorafas GH,Tsiotou AG,Tsiotos GG

更新日期：2000-02-01 00:00:00

abstract：:Surgery is, and always has been, the main treatment modality of solid tumours. For a long period, it consisted of a number of surgical procedures dictated by basic oncologic principles, most of which are still adhered to. Over the last few decades, increased understanding of the disease, new or improved diagnostic fac...

journal_title：Cancer treatment reviews

authors： Bremers AJ,Rutgers EJ,van de Velde CJ

更新日期：1999-12-01 00:00:00

abstract：:Metastatic melanoma is an incurable condition with a median survival of about 6 months. Chemotherapy can result in objective tumour responses but only in a minority of cases and remissions are short-lived, 3-6 months. DTJC is the most active single agent with response rates of 15-20% and although combination chemother...

journal_title：Cancer treatment reviews

authors： Chowdhury S,Vaughan MM,Gore ME

更新日期：1999-10-01 00:00:00

abstract：:A potential new therapy for cancer is active specific immunotherapy with melanoma antigen (MAGE) gene products. The MAGE gene family comprizes a series of 12 closely related genes, some of which have been shown to be expressed in a variety of tumours of different histological origin. Peptides encoded by the MAGE genes...

journal_title：Cancer treatment reviews

authors： Gillespie AM,Coleman RE

更新日期：1999-08-01 00:00:00

abstract：:Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a ...

journal_title：Cancer treatment reviews

authors： Terwogt JM,Nuijen B,Huinink WW,Beijnen JH

更新日期：1997-03-01 00:00:00

abstract：:Patient-controlled analgesia (PCA) was administered in the domiciliary environment in 143 pre-terminally and terminally ill tumour patients suffering either from excruciating chronic pain or severe chronic/acute complex pain that could not be relieved adequately by oral analgesia. Morphine solutions were infused subcu...

journal_title：Cancer treatment reviews

authors： Meuret G,Jocham H

更新日期：1996-01-01 00:00:00

abstract：:The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

journal_title：Cancer treatment reviews

authors： Bonneterre J,Mercier M

更新日期：1993-04-01 00:00:00

abstract：:Two regimens were tested, CHAP I and CHAP II, the latter, a hexamethylmelamine dosage-intensive regimen, first as second line (salvage) therapy and then as primary therapy. Both produced the most successful results achieved in the Mount Sinai series up to the time of their introduction, when compared to their predeces...

journal_title：Cancer treatment reviews

authors： Bruckner HW,Cohen C,Mandeli J,Chesser MR,Kabakow B,Wallach R,Holland J

更新日期：1991-03-01 00:00:00

abstract：:We have established that drug resistance can be expressed following in vitro exposure of tumour cells not only to antitumor drugs but also to fractionated X-irradiation. These data therefore suggest a biological basis for the clinical problem of drug resistance that can occur in patients with previously irradiated tum...

journal_title：Cancer treatment reviews

authors： Hill BT,Whelan RD,Hosking LK,Bedford P,Dempke WC,Shellard SA

更新日期：1990-12-01 00:00:00

abstract：:Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral ...

journal_title：Cancer treatment reviews

authors： Herrmann DB,Pahlke W,Opitz HG,Bicker U

更新日期：1990-09-01 00:00:00

abstract：:We have previously shown that the stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK monomer) leads to a good tolerance of otherwise lethal multiple ara-C doses and an increased survival of ara-C + peptide treated mice. This effect was due to the prevention of drug-induced CFU-S proliferation, thus keeping stem...

journal_title：Cancer treatment reviews

authors： Paukovits WR,Moser MH,Binder KA,Paukovits JB

更新日期：1990-09-01 00:00:00

abstract：:The present study describes a female child, who had a primary defect in the ability of her T-cells to secrete interleukin-2. Numbers of B- and T-cells were normal, but their functions were severely deficient. The patient had decreased immunoglobulins and poor ability to mount antibody responses. Phytohemagglutinin (PH...

journal_title：Cancer treatment reviews

authors： Pahwa R,Paradise C,Good RA

更新日期：1989-06-01 00:00:00

abstract：:Thirty-one patients with metastatic renal cell carcinoma were seen at the Centre Léon Bérard from October 1987 to October 1988. According to our protocol, 11 were excluded leaving 20 in the study. The median age was 55 years (range 36 to 79 years). The median number of metastases was 9 (range 2 to 29) and the median n...

journal_title：Cancer treatment reviews

authors： Philip T,Mercatello A,Negrier S,Philip I,Rebattu P,Kaemmerlin P,Gaspard M,Tognier E,Combaret V,Bijmann JT

更新日期：1989-06-01 00:00:00

abstract：:The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), endometrial hyperplasia, benign prostatic hypertrophy, contraception, anorexia, cachexia and weight loss is reviewed, concluding with a toxicity pro...

journal_title：Cancer treatment reviews

authors： Schacter L,Rozencweig M,Canetta R,Kelley S,Nicaise C,Smaldone L

更新日期：1989-03-01 00:00:00

abstract：:Our approach to develop platinum complexes with a selective effect on the hormone-dependent MC by exchanging the two NH3 groups of cisplatin by an 1,2-bis(4-hydroxy-phenyl)ethylenediamine derivative which possesses estrogenic activity, was successful. The most interesting compound of this new platinum complex series, ...

journal_title：Cancer treatment reviews

authors： Engel J,Schönenberger H,Lux F,Hilgard P

更新日期：1987-12-01 00:00:00

abstract：:In the early stages of this phase I study the tolerance of carboplatin intraperitoneally was good. Pharmacokinetic profiles suggest a possible therapeutic advantage for giving the drug intraperitoneally for the treatment of tumour nodules situated in the peritoneum. The extent of penetration of carboplatin through tum...

journal_title：Cancer treatment reviews

authors： McVie JG,ten Bokkel Huinink W,Dubbelman R,Franklin H,van der Vijgh W,Klein I

更新日期：1985-09-01 00:00:00

abstract：:The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in ce...

journal_title：Cancer treatment reviews

authors： Coltman CA Jr,Osborne CK

更新日期：1984-12-01 00:00:00

abstract：:Twenty patients with malignant lymphomas refractory to prior combination chemotherapy were treated with ifosfamide (40 mg/kg/day i.v. days 1-5) and etoposide (120 mg/m2/day i.v., days 1, 3, 5). Altogether, 56 courses of treatment were given with prophylaxis of urinary side effects by mesna (8 mg/kg i.v. 0, 4, 8 hours ...

journal_title：Cancer treatment reviews

authors： Scheulen ME,Bremer K,Niederle N,Seeber S

更新日期：1983-09-01 00:00:00

abstract：:In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...

journal_title：Cancer treatment reviews

authors： Scheulen ME,Niederle N,Bremer K,Schütte J,Seeber S

更新日期：1983-09-01 00:00:00